Cilostazol Dexborneol

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H27N5O2.C10H18O
Molecular Weight	523.71
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](O)C2.O=C3CCC4=C(N3)C=CC(OCCCCC5=NN=NN5C6CCCCC6)=C4

InChI

InChIKey=GYOUKZRGDOIBGD-VTLWDLMQSA-N

InChI=1S/C20H27N5O2.C10H18O/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16;1-9(2)7-4-5-10(9,3)8(11)6-7/h10-11,14,16H,1-9,12-13H2,(H,21,26);7-8,11H,4-6H2,1-3H3/t;7-,8+,10+/m.1/s1

HIDE SMILES / InChI

Molecular Formula	C20H27N5O2
Molecular Weight	369.4607
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H18O
Molecular Weight	154.2493
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=146824
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11830753

Cilostazol is a PDE3 inhibitor which is used for the treatment of intermittent claudication. The drug positively affects the platelet aggregation and may be used off-label as a measure to prevent coronary thrombosis/restenosis and stroke recurrence.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 3 61 Target ID: CHEMBL2094125 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=146824	Inhibitor 8504		0.57 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Intermittent claudication 12 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=146824	Palliative		Approved 8583	CILOSTAZOL Approved Use Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
701 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CILOSTAZOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
13724 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CILOSTAZOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CILOSTAZOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
3.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020863s011lbl.pdf			CILOSTAZOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31401	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31401
ChemicalBook	CB2362876	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2362876
eMolecules	27518122	https://www.emolecules.com/cgi-bin/more?vid=27518122
eMolecules	535670	https://www.emolecules.com/cgi-bin/more?vid=535670
MolPort	MolPort-001-758-007	https://www.molport.com/shop/molecule-link/MolPort-001-758-007
Selleck Chemicals	Cilostazol	http://www.selleckchem.com/products/Cilostazol.html
ZINC	ZINC000001552174	http://zinc15.docking.org/substances/ZINC000001552174

PubMed

Title	Date	PubMed
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.	2003-09	12714375
A paclitaxel-eluting stent for the prevention of coronary restenosis.	2003-04-17	12700373
Pharmacotherapy as adjunctive treatment for serious foot wounds in the patient with diabetes: a case study.	2003-04	12732740
Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block.	2003-04	12684307
Cilostazol: an "intermittent claudication" remedy for the management of third-degree AV block.	2003-04	12684279
Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.	2003-02	12624709
Inhibitory action of cilostazol, a phosphodiesterase III inhibitor, on catecholamine secretion from cultured bovine adrenal chromaffin cells.	2003-01	12688393
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.	2002-12-15	12480040
Pharmacotherapy for peripheral arterial disease: emerging therapeutic options.	2002-12-05	12463615
Can claudication be improved with medication?	2002-12	12478498
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.	2002-12	12473004
Pharmacologic therapy for peripheral arterial disease and claudication.	2002-12	12469066
Spontaneous recanalization of arterial occlusions: an unusual mechanism for symptomatic improvement.	2002-12	12469047
Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.	2002-12	12463722
Thermally-prepared polymorphic forms of cilostazol.	2002-12	12434391
Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells.	2002-12	12419709
Management of patients with intermittent claudication.	2002-11	12469984
Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.	2002-10-09	12365857
Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.	2002-10	12533252
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.	2002-10	12370857
New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation.	2002-10	12352320
Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).	2002-09-15	12231079
Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.	2002-09	12652111
[State of treatment of coronary artery disease by drug releasing stents].	2002-09	12378395
Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.	2002-09	12181427
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.	2002-08	12177649
Polymorphic forms of cilostazol.	2002-08	12154319
Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome.	2002-07	12139296
Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature.	2002-07	12112901
Cilostazol enhances IL-1beta-induced NO production and apoptosis in rat vascular smooth muscle via PKA-dependent pathway.	2002-07	11955955
[Effect of cilostazol on adhesion molecules of STZ-induced diabetic rats].	2002-06-10	12126539
Peripheral arterial disease.	2002-06	12230639
[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].	2002-06	12219692
A rational approach to diagnosis and treatment of intermittent claudication.	2002-05	12018666
Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.	2002-04-16	11951094
Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.	2002-04	11956507
The herbal medicine Dai-kenchu-to and one of its active components [6]-shogaol increase intestinal blood flow in rats.	2002-03-15	12148698
Treating peripheral arterial disease in patients with diabetes.	2002-03	12180355
Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.	2002-03	12180354
The pharmacology of cilostazol.	2002-03	12180353
Recent advances in antiplatelet agents.	2002-03	11945125
Effects of a single oral dose of cilostazol on epicardial coronary arteries and hemodynamics in humans.	2002-03	11922271
Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.	2002-03	11892686
Cilostazol.	2002-02-01	11862634
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes.	2002-02	11935149
[Etiology, pathogenesis and management of senile inflammatory pulmonary diseases].	2002-01	11925914
Pharmacologic treatment for intermittent claudication.	2002	12710846
Cilostazol treatment of claudication in diabetic patients.	2002	12564659
Rapid ventricular tachycardias associated with cilostazol use.	2002	12075874
Three cases of digital ischemia successfully treated with cilostazol.	2001-11	11958391

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage of cilostazol tablets is 100 mg b.i.d. taken at least half an hour before or 2 hours after breakfast and dinner.

Route of Administration: Oral

In Vitro Use Guide

In vitro assay of anti-platelet effects of cilostazol against collagen-induced aggregation using Multiplate produced a graded dose-dependent inhibition curve with IC50 value of 75.4 ± 2.4 uM while it showed a highly sensitive and all-or-none type inhibition response from 25 uM in PFA-100.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 17:38:43 GMT 2025` Edited by `admin` on `Wed Apr 02 17:38:43 GMT 2025`
Record UNII	463NWV9Y86
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Cilostazol Dexborneol

Preferred Name

English

Code System Code Type Description

FDA UNII

463NWV9Y86

Created by admin on Wed Apr 02 17:38:43 GMT 2025 , Edited by admin on Wed Apr 02 17:38:43 GMT 2025

PRIMARY

PUBCHEM

169490784

Created by admin on Wed Apr 02 17:38:43 GMT 2025 , Edited by admin on Wed Apr 02 17:38:43 GMT 2025

PRIMARY

Related Record Type Details


					N7Z035406B

CILOSTAZOL

PARENT -> SALT/SOLVATE

Amount: